度拉糖肽辅助治疗调控初发2型糖尿病伴肥胖患者代谢紊乱的影响  

Effect of Dulaglutide Adjuvant Therapy on Metabolic Disorder in Newly Diagnosed Type 2 Diabetes Mellitus Patients with Obesity

作　　者：奚雯菲 杨静 杜首作 XI Wenfei;YANG Jing;DU Shouzuo(Department of Endocrinology,Xiangcheng People's Hospital,Suzhou 215131,Jiangsu,China)

机构地区：[1]苏州市相城人民医院内分泌科,江苏苏州215131

出　　处：《糖尿病新世界》2025年第4期102-105,共4页Diabetes New World

摘　　要：目的 研究初发2型糖尿病伴肥胖患者以度拉糖肽辅助治疗对代谢紊乱指标的影响。方法 选择2021年1月—2024年3月相城人民医院接诊的初发2型糖尿病伴肥胖患者70例,按照不同治疗方法分组,对照组(35例)采取二甲双胍药物治疗,观察组(35例)在对照组基础上以度拉糖肽辅助治疗。对比两组患者治疗前后血糖、血脂代谢水平及不良反应发生率。结果 治疗后,观察组空腹血糖、餐后2 h血糖、糖化血红蛋白、总胆固醇、甘油三酯、低密度脂蛋白水平均低于对照组,高密度脂蛋白水平高于对照组,差异均有统计学意义(P均<0.05)。两组用药后不良反应发生率比较,差异无统计学意义(P>0.05)。结论 初发2型糖尿病伴肥胖患者以度拉糖肽辅助治疗能够有效调控代谢紊乱指标,同时不增加不良反应。Objective To study the effect of dulaglutide adjuvant therapy on metabolic disorder indexes in patients of newly diagnosed type 2 diabetes mellitus with obesity.Methods A total of 70 patients with newly diagnosed type 2 diabetes mellitus and obesity admitted to Xiangcheng People's Hospital from January 2021 to March 2024 were selected.They were grouped according to different treatment methods.The control group(35 cases) was treated with metformin.The observation group(35 cases) was treated with dulaglutide on the basis of the control group.The blood glucose,blood lipid metabolism levels before and after treatment and the incidence of adverse reactions were compared between groups.Results After treatment,the levels of fasting plasma glucose,2-hour postprandial plasma glucose,glycated hemoglobin A1c,total cholesterol,triglyceride and low density lipoprotein in the observation group were lower than the control group,the level of high density lipoprotein was higher than the control group,the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of adverse reactions between groups after treatment(P>0.05).Conclusion Adjuvant therapy with dulaglutide in patients with newly diagnosed type 2 diabetes mellitus and obesity can effectively regulate metabolic disorder indicators without increasing adverse reactions.

关 键 词：度拉糖肽 初发2型糖尿病 肥胖 代谢紊乱 

分 类 号：R587[医药卫生—内分泌]